

Erika Vacchelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1441930/publications.pdf>

Version: 2024-02-01

88
papers

12,098
citations

34493

54
h-index

56606

87
g-index

88
all docs

88
docs citations

88
times ranked

19399
citing authors

#	ARTICLE	IF	CITATIONS
1	A loss-of-function polymorphism in <i>ATG16L1</i> compromises therapeutic outcome in head and neck carcinoma patients. <i>Oncolmmunology</i> , 2022, 11, 2059878.	2.1	3
2	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28
3	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. <i>Oncolmmunology</i> , 2021, 10, 1859064.	2.1	6
4	Trial watch: STING agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777624.	2.1	148
5	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1777625.	2.1	91
6	Autophagy-mediated metabolic effects of aspirin. <i>Cell Death Discovery</i> , 2020, 6, 129.	2.0	17
7	Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. <i>Oncolmmunology</i> , 2020, 9, 1796002.	2.1	63
8	No impact of cancer and plague-relevant <i>FPR1</i> polymorphisms on COVID-19. <i>Oncolmmunology</i> , 2020, 9, 1857112.	2.1	4
9	Chemical activation of SAT1 corrects diet-induced metabolic syndrome. <i>Cell Death and Differentiation</i> , 2020, 27, 2904-2920.	5.0	22
10	The ambiguous role of FPR1 in immunity and inflammation. <i>Oncolmmunology</i> , 2020, 9, 1760061.	2.1	26
11	Trial watch: TLR3 agonists in cancer therapy. <i>Oncolmmunology</i> , 2020, 9, 1771143.	2.1	116
12	Contribution of annexin A1 to anticancer immunosurveillance. <i>Oncolmmunology</i> , 2019, 8, e1647760.	2.1	27
13	A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. <i>Oncolmmunology</i> , 2019, 8, e1657375.	2.1	56
14	Crizotinib-induced immunogenic cell death in non-small cell lung cancer. <i>Nature Communications</i> , 2019, 10, 1486.	5.8	189
15	Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. <i>Oncolmmunology</i> , 2019, 8, e1498285.	2.1	25
16	TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves. <i>Oncolmmunology</i> , 2018, 7, e1462431.	2.1	82
17	Organs on chip approach: a tool to evaluate cancer-immune cells interactions. <i>Scientific Reports</i> , 2017, 7, 12737.	1.6	69
18	Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance. <i>Cancer Cell</i> , 2016, 30, 147-160.	7.7	410

#	ARTICLE	IF	CITATIONS
19	Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1. <i>Oncolmmunology</i> , 2016, 5, e1118600.	2.1	14
20	The ratio of CD8 ⁺ /FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma <i>in situ</i> . <i>Oncolmmunology</i> , 2016, 5, e1218106.	2.1	50
21	Autophagy induction for the treatment of cancer. <i>Autophagy</i> , 2016, 12, 1962-1964.	4.3	50
22	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolmmunology</i> , 2016, 5, e1214790.	2.1	64
23	Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy. <i>Cancer Research</i> , 2016, 76, 3122-3126.	0.4	47
24	Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1139275.	2.1	21
25	Trial Watch—Immunostimulation with cytokines in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1115942.	2.1	52
26	Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells. <i>Oncolmmunology</i> , 2016, 5, e1064581.	2.1	14
27	Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. <i>Oncolmmunology</i> , 2016, 5, e1149673.	2.1	136
28	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	2.2	317
29	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e985940.	2.1	47
30	Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate <i>in vivo</i> . <i>Cell Cycle</i> , 2015, 14, 2399-2407.	1.3	27
31	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	2.1	237
32	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367
33	Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy. <i>Oncotarget</i> , 2015, 6, 20840-20850.	0.8	50
34	Autocrine signaling of type 1 interferons in successful anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e988042.	2.1	27
35	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
36	Trial watch. <i>Oncolmmunology</i> , 2014, 3, e29030.	2.1	51

#	ARTICLE	IF	CITATIONS
37	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	2.1	686
38	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e29179.	2.1	76
39	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27048.	2.1	69
40	Trial watch: IDO inhibitors in cancer therapy. <i>Oncolmmunology</i> , 2014, 3, e957994.	2.1	223
41	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
42	Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set. <i>Oncolmmunology</i> , 2014, 3, e28473.	2.1	112
43	Coffee induces autophagy in vivo. <i>Cell Cycle</i> , 2014, 13, 1987-1994.	1.3	49
44	Regulation of Autophagy by Cytosolic Acetyl-Coenzyme A. <i>Molecular Cell</i> , 2014, 53, 710-725.	4.5	412
45	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27878.	2.1	134
46	Cancer cellâ€™s autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. <i>Nature Medicine</i> , 2014, 20, 1301-1309.	15.2	823
47	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e28344.	2.1	31
48	Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. <i>Cell Death and Differentiation</i> , 2014, 21, 59-68.	5.0	83
49	Regulation of autophagy by stress-responsive transcription factors. <i>Seminars in Cancer Biology</i> , 2013, 23, 310-322.	4.3	215
50	Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. <i>Immunity</i> , 2013, 38, 729-741.	6.6	572
51	Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses. <i>Oncogene</i> , 2013, 32, 4995-5004.	2.6	108
52	Fluorescent Biosensors for the Detection of HMGB1 Release. <i>Methods in Molecular Biology</i> , 2013, 1004, 43-56.	0.4	12
53	Crosstalk between ER stress and immunogenic cell death. <i>Cytokine and Growth Factor Reviews</i> , 2013, 24, 311-318.	3.2	177
54	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23803.	2.1	92

#	ARTICLE	IF	CITATIONS
55	Current trends of anticancer immunochemotherapy. <i>Oncolmmunology</i> , 2013, 2, e25396.	2.1	26
56	ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy. <i>Oncolmmunology</i> , 2013, 2, e24568.	2.1	75
57	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23082.	2.1	130
58	Vitamin B6 metabolism influences the intracellular accumulation of cisplatin. <i>Cell Cycle</i> , 2013, 12, 417-421.	1.3	26
59	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e25771.	2.1	150
60	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolmmunology</i> , 2013, 2, e26494.	2.1	50
61	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
62	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23510.	2.1	153
63	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e26621.	2.1	101
64	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e24238.	2.1	58
65	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e24850.	2.1	49
66	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e25595.	2.1	83
67	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e25238.	2.1	132
68	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e24612.	2.1	175
69	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolmmunology</i> , 2012, 1, 894-907.	2.1	194
70	Independent transcriptional reprogramming and apoptosis induction by cisplatin. <i>Cell Cycle</i> , 2012, 11, 3472-3480.	1.3	32
71	Loss-of-function alleles of <i>P2RX7</i> and <i>TLR4</i> fail to affect the response to chemotherapy in non-small cell lung cancer. <i>Oncolmmunology</i> , 2012, 1, 271-278.	2.1	36
72	Anticancer activity of cardiac glycosides. <i>Oncolmmunology</i> , 2012, 1, 1640-1642.	2.1	89

#	ARTICLE	IF	CITATIONS
73	Trial watch. Oncolmunology, 2012, 1, 179-188.	2.1	104
74	Trial watch. Oncolmunology, 2012, 1, 1557-1576.	2.1	110
75	Premortem autophagy determines the immunogenicity of chemotherapy-induced cancer cell death. Autophagy, 2012, 8, 413-415.	4.3	90
76	Trial Watch. Oncolmunology, 2012, 1, 699-739.	2.1	184
77	Trial Watch. Oncolmunology, 2012, 1, 306-315.	2.1	70
78	Trial Watch. Oncolmunology, 2012, 1, 493-506.	2.1	86
79	Pro-autophagic polyphenols reduce the acetylation of cytoplasmic proteins. Cell Cycle, 2012, 11, 3851-3860.	1.3	91
80	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 257-269.	2.9	122
81	Prognostic Impact of Vitamin B6 Metabolism in Lung Cancer. Cell Reports, 2012, 2, 1472.	2.9	0
82	Trial watch. Oncolmunology, 2012, 1, 1111-1134.	2.1	152
83	Trial Watch: Monoclonal antibodies in cancer therapy. Oncolmunology, 2012, 1, 28-37.	2.1	103
84	Trial watch. Oncolmunology, 2012, 1, 1323-1343.	2.1	203
85	Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death. Science Translational Medicine, 2012, 4, 143ra99.	5.8	367
86	Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice. Science, 2011, 334, 1573-1577.	6.0	1,159
87	Cell Death Signaling and Anticancer Therapy. Frontiers in Oncology, 2011, 1, 5.	1.3	46
88	Mitochondrial gateways to cancer. Molecular Aspects of Medicine, 2010, 31, 1-20.	2.7	239